Tianjin Study Center: A hospital-based-case-control study of lymphoma in Asia (AsiaLymph)

Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, Riverside Five, Suite 400, Room 4025, 8490 Progress Drive, Frederick, MD 21701, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), is anticipating to award a Firm-Fixed Price non-competitive purchase order to Tianjin Medical University, in Tianjin, China to coordinate study activities at 5 collaborating hospitals in Tianjin. The collaborating hospitals are Tianjin Medical University Institute and Hospital, Tianjin Medical University General Hospital, Tianjin First Center Hospital, Second Hospital of Tianjin Medical University, and Institute of Hematology & Blood Diseases Hospital. The services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 541990 and the business size standard is $14 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award. The contribution of environmental, occupational and genetic factors to lymphoma has generated a series of novel, cutting edge findings in studies of Caucasians. However, the ability to follow-up, confirm and extend these observations has become limited in Western populations, due to the low prevalence and limited range of several important chemical exposures and the high to complete linkage disequilibrium between key candidate genetic loci. Therefore it is necessary to investigate populations that differ from Caucasians in both exposure patterns and underlying genetic structure. To this end, the National Cancer Institute is conducting a hospital-based case-control study of lymphoma in Eastern Asia (i.e. AsiaLymph). The major postulated risk factors for evaluation in this study are chemical exposures, genetic susceptibility, and infectious agents. A particularly noteworthy aspect of AsiaLymph is central pathology review with immunophenotyping, which will enable accurate analysis of findings by molecular and histologic subtypes. AsiaLymph should confirm and extend previous findings, and yield novel insights into the causes of lymphoma in both Asia and the West. Only Tianjin Medical University have the target population and data that can be produced comparably to that of the other AsiaLymph centers, and the maintenance of this comparability and continuity is crucial to the validity of the ongoing data collection process in the Tianjin area. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 12:00 PM EST, on August 29, 2013. For further information, please contact Brenda Oberholzer, Contracting Officer via electronic mail at oberholzerb@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) thru sam.gov. Reference: NCI-34408-11 on all correspondence.